SequelSEC

Aspira Women's Health Inc. AWHL

In Vitro & In Vivo Diagnostic Substances · CIK 0000926617 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.37M
Fiscal year ended 2026-06-30
Operating income
-$6.90M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$4.67MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.11Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue13.6×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the In Vitro & In Vivo Diagnostic Substances filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin1724.5%100th
Revenue YoY growth8475.0%100th
Current ratio1.17x7th
Net margin-3725.9%15th
Operating margin-2307.0%15th
R&D / revenue839.1%85th
SBC / revenue154.8%85th
FCF margin-2053.9%22th
CapEx / revenue4.7%44th

Aspira Women's Health Inc. (AWHL) reported revenue of $2.37M and net income of -$10.00M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Aspira Women's Health Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

Aspira Women's Health Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$2.37M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$6.90M
Net income-$10.00M
Research & development$3.12M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$8.80M
General & administrative$6.47M
Selling & marketing$2.33M

Balance

Aspira Women's Health Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$477.00K
Total assets$4.44M
Current assets$2.80M
Total liabilities$11.69M
Current liabilities$5.34M
Total equity incl. NCI-$7.26M
Temporary (mezzanine) equityUnavailable
Inventory$231.00K
Accounts receivable$1.48M
GoodwillUnavailable
Long-term debt$961.00K
Accounts payable$2.75M

Cash flow

Aspira Women's Health Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$4.56M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$4.04M
Net change in cash-$1.07M
Stock-based compensation$473.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$168.00K

Derived

Aspira Women's Health Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-291.7%
FCF marginUnavailable
SBC / revenue20.0%
Current ratio0.52x
Revenue YoY growth-50.5%
Net margin-422.9%
R&D / revenue131.8%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AWHL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-01View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-19View SEC filing

Companies in the same industry

ACHV BMRA BZYR CDIO CLDX ICCC IDXX IMDX LNTH MYGN NEOG NTLA

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.